Cargando…

Lenvatinib Beyond First-Line Therapy in Patients With Advanced Biliary Tract Carcinoma

INTRODUCTION: Lenvatinib, a multiple receptor tyrosine kinase inhibitors that target vascular endothelial growth factor receptors and fibroblast growth factor receptors, recently demonstrated a treatment effect in various tumors. This study evaluated the efficacy and safety of lenvatinib for patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yunchao, Yang, Xiaobo, Wang, Dongxu, Yang, Xu, Wang, Yanyu, Long, Junyu, Zhou, Jinxue, Lu, Zhenhui, Mao, Yilei, Sang, Xinting, Guan, Mei, Zhao, Haitao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928459/ https://www.ncbi.nlm.nih.gov/pubmed/35311147 http://dx.doi.org/10.3389/fonc.2022.785535

Ejemplares similares

The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study
por: Wang, Dongxu, et al.
Publicado: (2021)

Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer
por: Zhu, Chengpei, et al.
Publicado: (2023)

Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients
por: Yang, Xu, et al.
Publicado: (2023)

Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma
por: Xie, Fucun, et al.
Publicado: (2022)

Mutational spectrum and precision oncology for biliary tract carcinoma
por: Lin, Jianzhen, et al.
Publicado: (2021)

Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study
por: Zhu, Chengpei, et al.
Publicado: (2023)

Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC
por: Wang, Yunchao, et al.
Publicado: (2023)

Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study
por: Zhang, Qiyi, et al.
Publicado: (2021)

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
por: Wang, Dongxu, et al.
Publicado: (2019)

Comprehensive analysis of coagulation indices for predicting survival in patients with biliary tract cancer
por: Ke, Xindi, et al.
Publicado: (2021)

Comparison of the Prognostic Value of Platelet-Related Indices in Biliary Tract Cancer Undergoing Surgical Resection
por: Sun, Lejia, et al.
Publicado: (2021)

Apatinib as non-first-line treatment in patients with Intrahepatic Cholangiocarcinoma
por: Mao, Jinzhu, et al.
Publicado: (2021)

Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study
por: Li, Qi, et al.
Publicado: (2022)

Controlling nutritional status score as a prognostic marker to predict overall survival in resected biliary tract cancers
por: Sun, Lejia, et al.
Publicado: (2021)

Lenvatinib as second-line treatment in patients with unresectable hepatocellular carcinoma: A retrospective analysis
por: Qin, He-nan, et al.
Publicado: (2022)

Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma
por: Wang, Ye, et al.
Publicado: (2022)

Comprehensive analysis of a ceRNA network reveals potential prognostic cytoplasmic lncRNAs involved in HCC progression
por: Bai, Yi, et al.
Publicado: (2019)

Exploring the function of stromal cells in cholangiocarcinoma by three-dimensional bioprinting immune microenvironment model
por: Li, Changcan, et al.
Publicado: (2022)

Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results
por: Ueno, Makoto, et al.
Publicado: (2020)

Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China
por: Shi, Changying, et al.
Publicado: (2022)

Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis
por: Luo, Jia, et al.
Publicado: (2022)

Identification of an m6A-Related Long Noncoding RNA Risk Model for Predicting Prognosis and Directing Treatments in Patients With Colon Adenocarcinoma
por: Liao, Wanying, et al.
Publicado: (2022)

Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma
por: Stoff, Ronen, et al.
Publicado: (2023)

Lenvatinib for Anaplastic Thyroid Cancer
por: Tahara, Makoto, et al.
Publicado: (2017)

Prioritizing key synergistic circulating microRNAs for the early diagnosis of biliary tract cancer
por: Su, Fei, et al.
Publicado: (2022)

Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers
por: Mao, Jinzhu, et al.
Publicado: (2021)

Integrated analysis of serum lipid profile for predicting clinical outcomes of patients with malignant biliary tumor
por: Sun, Lejia, et al.
Publicado: (2020)

Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers
por: Yang, Xu, et al.
Publicado: (2021)

Biliary Tract Carcinogenesis Model Based on Bile Metaproteomics
por: Arteta, Ariel A., et al.
Publicado: (2020)

Comparing the efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of phase III trials
por: Wang, Dongxu, et al.
Publicado: (2020)

PD-1 Inhibitors Could Improve the Efficacy of Chemotherapy as First-Line Treatment in Biliary Tract Cancers: A Propensity Score Matching Based Analysis
por: Gou, Miaomiao, et al.
Publicado: (2021)

The diagnostic and prognostic role of RhoA in hepatocellular carcinoma
por: Bai, Yi, et al.
Publicado: (2019)

Sintilimab Combined with Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma in Second-Line Setting—A Multi-Center Observational Study
por: Ding, Xiaoyan, et al.
Publicado: (2022)

Efficacy and Safety of First-Line Chemotherapies for Patients With Advanced Biliary Tract Carcinoma: A Systematic Review and Network Meta-Analysis
por: Jiang, Yanfeng, et al.
Publicado: (2021)

Metformin and Biliary Tract Cancer in Patients With Type 2 Diabetes
por: Tseng, Chin-Hsiao
Publicado: (2020)

Prognostic Significance of Sarcopenia in Advanced Biliary Tract Cancer Patients
por: Lee, Byung min, et al.
Publicado: (2020)

The Evolving Role of Radiation Therapy in the Treatment of Biliary Tract Cancer
por: Gkika, Eleni, et al.
Publicado: (2020)

Application of a 3D Bioprinted Hepatocellular Carcinoma Cell Model in Antitumor Drug Research
por: Sun, Lejia, et al.
Publicado: (2020)

Intraductal papillary mucinous neoplasm of the biliary tract in the caudate lobe of the liver: a case report and literature review
por: Zhu, Xunhao, et al.
Publicado: (2023)

Recent Advances in the Mechanism Research and Clinical Treatment of Anti-Angiogenesis in Biliary Tract Cancer
por: Wang, Yue, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m4ar1etdqdooijfmifp1od5rtf